Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens

European Neuropsychopharmacology

Volumn 6, Issue 1, 1996, Pages 29-38

  Marcus, Monica M ^a   Nomikos, George G ^a   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antipsychotic drugs; Dopamine release; In vivo voltammetry; Nucleus accumbens; Nucleus accumbens core; Nucleus accumbens shell

Indexed keywords

AMPEROZIDE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; PARGYLINE; RACLOPRIDE; RISPERIDONE; RITANSERIN; SEROTONIN 1 RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; DOPAMINE RELEASE; HISTOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT;

EID: 0030010159     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0924-977X(95)00056-U     Document Type: Article

References (65)

1. Andersson, J.L., Marcus, M., Nomikos, G.G. and Svensson, T.H. (1994) Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system. Naunyn-Schmiedebergs Arch. Pharmacol. 349, 236-243.
2. Andersson, J.L., Nomikos, G.G., Marcus, M., Hertel, P., Mathé J.M. and Svensson, T.H. (1995) Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system. Naunyn-Schmiedebergs Arch. Pharmacol. 352, 374-385.
3. Axelsson, R., Nilsson, A., Christensson, E. and Björk, A. (1991) Effects of amperozide in schizophrenia. Psychopharmacology 104, 287-292.
4. 2 receptor subtypes: a family re-united? Trends Pharmacol. Sci. 16, 105-110.
5. Björk, A., Bergman, I. and Gustavsson, G. (1992) Amperozide in the treatment of schizophrenic patients. A preliminary report. In: H.Y. Meltzer (Ed.), Novel Antipsychotic Drugs. Raven, New York, pp. 47-57.
6. Brog, J.S., Salyapongse. A., Deutch, A.Y. and Zahm, D.S. (1993) The pattern of afferent innervation of the core and shell in the "accumbens' part of the rat ventral striatum: Immunohistochemical detection of retrogradely transported Fluoro-Gold. J. Comp. Neurol. 338, 255-278.
7. Conley, R.R., Schultz, S.C., Baker, R.W., Collins, J.F. and Bell, J.A. (1988) Clozapine efficacy in schizophrenic nonresponders. Psychopharmacol. Bull. 24, 269-274.
8. Coward, D.M. (1992) General pharmacology of clozapine. Br. J. Psychiatry 160 (Suppl. 17), 5-11.
9. Deutch, A.Y. (1993) Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinsson's disease. J. Neural Transm. Gen. Sect. 91, 197-221.
10. Deutch, A.Y. and Cameron, D.S. (1992) Pharmacological characterization of dopamine system in the nucleus accumbens core and shell. Neuroscience 46, 49-56.
11. Deutch, A.Y., Lee, M.C. and Iadarola, M.J. (1992) Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: The nucleus accumbens shell as a locus of antipsychotic action. Mol. Cell. Neurosci. 3, 332-341.
12. Deutch, A.Y., Mogahaddam, B., Innis, R.B., Krystal, J.H., Aghajanian, G.K., Bunney, B.S. and Charney, D.S. (1991) Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophr. Res. 4, 121-156.
13. Farde, L., Nordström, A.L., Wiesel, F.-A., Pauli, S., Halldin, C. and Sedvall, G. (1992) Positron emission tomografic analysis of central, D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptic and clozapine. Arch. Gen. Psychiatry 49, 538-544.
14. 2-dopamine occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry 45, 71-76.
15. Fitton, A. and Heel, R.C. (1990) Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40, 722-747.
16. Gelders, Y.G. (1989) Thymostenic agents, a novel approach in the treatment of schizophrenia. Br. J. Psychiatry 155 (Suppl. 5), 33-36.
17. 2 receptor blockers in the treatment of chronic schizophrenia. Clin. Neuropharmacol. 9, 327-327.
18. Gonon, F.G. (1987) In vivo electrochemical monitoring of dopamine release. In: J.B. Justice Jr. (Ed.), Voltammetry in Neurosciences. Humana Press, Englewood Cliffs, NJ, pp. 163-183.
19. Gonon, F.G. (1988) Nonlinear relationship between impulse flow and dopamine release by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience 24, 19-28.
20. Gonon, F., Buda, M. and Pujol, J.F. (1984a) Treated carbon fibre electrodes for measuring catechols and ascorbic acid. In: C.A Marsden (Ed.), Measurement of Neurotransmittor Release in vivo. Wiley, Chichester, U.K., pp. 153-171.
21. Gonon, F.G., Navarre, F. and Buda, M.J. (1984b) In vivo monitoring of dopamine release in the rat brain with differential normal pulse voltammetry. Anal. Chem. 56, 573-575.
22. Grenhoff, J., Tung, C., Ugedo, L. and Svensson, T.H. (1990) Effect of amperozide, a putative antipsychotic drug, on rat midbrain dopamin neurons recorded in vivo. Pharmacol. Toxicol. (Suppl. 1), 29-33.
23. Gustafsson, B. and Christensson, E. (1990) Amperozide - a new putatively antipsychotic drug with a limbic mode of action on dopamine mediated behaviour. Pharmacol. Toxicol. (Suppl. 1), 12-17.
24. 2-dopamine receptor binding in the post-mortem human brain. An autoradiographic study. Eur. Neuropsychopharmacol. 5, 19-25.
25. Hand T.H., Hu, X-T. and Wang, R.Y. (1987) Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons. Brain Res. 415, 257-269.
26. Heimer, L., Zahm, D,.S., Churchill, L., Kalivas, P.W. and Wohltmann, C. (1991) Specificity in the projection patterns of accumbal core and shell. Neuroscience 41, 89-126.
27. 2 antagonistic properties. J. Pharmacol. Exp. Ther. 244, 685-693.
28. Kane, J., Honigfeld, G., Singer, J., Meltzer, H. and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psychiatry 45, 789-796.
29. 3H-raclopride. Biochem. Pharmacol. 34, 2251-2259.
30. 2 antagonist. Mol. Pharmacol. 27, 600-611.
31. 2 receptors. Psychopharmacology 112, S40-S54.
32. Leysen, J.E. and Niemegeers, C.J.E. (1985) Neuroleptics. In: A. Lajtha (Ed.), Handbook in Neurochemistry, Vol. 9. Plenum, New, York, pp. 331-361.
33. 2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J. Pharmacol. Exp. Ther. 265, 498-508.
34. i values. J. Pharmacol. Exp. Ther. 251, 238-246.
35. Meltzer, H.Y. and Nash, J.F. (1991) VII. Effects of antipsychotic drugs on serotonin receptors. Pharmacol. Rev. 43, 587-604.
36. 2 receptor occupancy: implications for antipsychotic action. Eur. J. Pharmacol. 216, 67-71.
37. Meredith, G.E., Agolia, R., Arts, M.P.M., Groenewegen, H.J. and Zahm, D.S. (1992) Morphological differences between projection neurons of the core and shell in the nucleus accumbens of the rat. Neuroscience 50, 149-162.
38. Moghaddam, B. and Bunney, B.S. (1990a) Acute effects of typical and atypical antipsychotic drug on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54, 1755-1760.
39. Moghaddam, B. and Bunney, B.S. (1990b) Utilization of microdialysis for assessing the release of mesotelencephalic dopamine folowing clozapine and other antipsychotic drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry 14, S51-S57.
40. Nomikos, G.G., Iurlo, M., Andersson, J.L., Kimura, K. and Svensson, T.H. (1994a) Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology 115, 147-156.
41. Nomikos, G.G., Marcus, M.M., Tham, C.S., Fibiger, H.C. and Svensson, T.H. (1994b) Selective actions of the novel atypical antipsychotic drug amperozide in the limbic forebrain. Soc. Neurosci. Abstr. 20, 1638.
42. 2-dopamine receptor occupancy examined by PET after single oral dose of haloperidol. Psychopharmacology 106, 433-438.
43. 2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 110, 365-367.
44. 2-Dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol. Psychiatry 33, 227-235.
45. 2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology 90, 287-294.
46. Paxinos, G. and Watson, C. (1986) The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic Press, Sydney.
47. Pazos, A., Cotrés, R. and Palacios, J.M. (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res. 346, 231-249.
48. Pehek, E.A., Meltzer, H.Y. and Yamamoto, B.K. (1993) The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux. Eur. J. Pharmacol. 240, 107-109.
49. Pennartz, C.M.A., Dolleman-Van der Weel, M.J. and da Silva, F.H.L. (1992) Differential membrane properties and dopamine effects in the shell and core of the rat nucleus accumbens studied in vitro. Neurosci. Lett. 136, 109-112.
50. Robertson, G.S., Matsumura, H. and Fibiger, H.C. (1994) Induction pattern of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Pharmacol. Exp. Ther. 271, 1058-1066.
51. Schooler, N.R. (1994) Negative symptoms in schizophrenia: Assessment of the effect of risperidone. J. Clin. Psychiatry 55 (Suppl. 5) 22-28.
52. Schotte, A., de Bruyckere, K., Janssen, P.F.M. and Leysen, J.E. (1989) Receptor occupancy by ritanserin and risperidone measured using ex vivo autoradiography. Brain Res. 500, 295-301.
53. Seeman, P. (1980) Brain dopamine receptors. Pharmacol. Rev. 32, 229-313.
54. 3) as a target for neuroleptics. Nature 347, 146-151.
55. 2 receptor binding study of risperidone and haloperidol. Pharmacol. Biochem. Behav. 47, 553-557.
56. 2 receptors as assessed by in vitro and in vivo binding. Eur. J. Pharmacol. 254, 73-81.
57. Svartengren, J. and Simonsson, P. (1990) Receptor binding properties of amperozide. Pharmacol. Toxicol. (Suppl. 1), 8-11.
58. 1-adrenoreceptor antagonism. J. Clin. Psychopharmacol. 15 (Suppl. 1), 11-18.
59. 2 antagonism. In: P.M. Vanhoutte, P.R. Saxena, R. Paoletti, N. Brunello and A.S. Jackson (Eds.), Serotonin. Kluwer Academic and Fondazione Giovanni Lorenzini, pp. 263-270.
60. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychpharmacology 98, 45-50.
61. 4 receptor with high affinity for the antipsychotic clozapine. Nature 350, 610-614.
62. White, F.J. and Wang, R.Y. (1983) Differential effect of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221, 1054-1055.
63. Zaborszky, L., Alheid, G.F., Beinfeld, M.C., Eidens, L.E., Heimer, L. and Palkovits, M. (1985) Cholecystokinin innervation of the ventral striatum: a morphological and radioimmunological study. Neuroscience 14, 427-453.
64. Zahm, D.S. and Brog, J.S. (1992) Commentary: On the significance of subterritories in the 'accumbens' part of the rat ventral striatum. Neuroscience 50, 751-767.
65. Zahm, D.S. and Heimer, L. (1990) Two transpallidal pathways originating in the rat nucleus accumbens. J. Comp. Neurol. 302, 437-446.